Diastolic Robotics' mission is to improve patient care. We want to:
To these ends Diastolic Robotics Incorporated (DRI) works in medicine and engineering, developing drug and device solutions.
Diastolic Robotics™ — also known as diarobo™ —
was started to commercialize products in the surgical robotics space, specifically
surgical tools for heart stabilization during coronary artery bypass procedures.
One such device was THASA, the Tissue and Heart Stabilization Tool, which is described
in United States patent:
6,210,323 Surgical arm and tissue stabilizer
THASA held sections of the heart still for coronary artery bypass grafting procedures, allowing work to progress off-pump.
Following that, DRI expanded into medical device consulting and software development. Some of the software projects include simulation and modelling programs:
Currently DRI's software projects include apps and other software for medical professionals. These projects include:
More recently, DRI is commercializing products for individualizing drug therapies, specifically neuromuscular blockers (NMB), but with many other indications in mind. NMB drugs are safe, but subject to frequent incidences of under- and overdosing due to dose-by-weight regimens. We have a solution that reduces, these incidences, as shown in a 60 patient clinical trial. Please view the NMB Projects page for the details.
diarobo and "Diastolic Robotics" are trademarks of Diastolic Robotics Incorporated
© 2012 Diastolic Robotics Incorporated